Mission Wealth Management LP Grows Stake in Becton, Dickinson and Company (NYSE:BDX)

Mission Wealth Management LP increased its position in Becton, Dickinson and Company (NYSE:BDX) by 23.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,360 shares of the medical instruments supplier’s stock after purchasing an additional 449 shares during the quarter. Mission Wealth Management LP’s holdings in Becton, Dickinson and Company were worth $576,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BDX. Commonwealth Equity Services LLC lifted its stake in shares of Becton, Dickinson and Company by 0.8% in the third quarter. Commonwealth Equity Services LLC now owns 84,714 shares of the medical instruments supplier’s stock worth $21,901,000 after acquiring an additional 648 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company by 3.4% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 25,820 shares of the medical instruments supplier’s stock valued at $6,675,000 after buying an additional 859 shares during the last quarter. FinTrust Capital Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 39.1% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 544 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 153 shares during the last quarter. Stratos Wealth Partners LTD. grew its position in shares of Becton, Dickinson and Company by 13.2% during the third quarter. Stratos Wealth Partners LTD. now owns 13,627 shares of the medical instruments supplier’s stock worth $3,523,000 after buying an additional 1,591 shares in the last quarter. Finally, Stratos Wealth Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 1.3% in the third quarter. Stratos Wealth Advisors LLC now owns 4,099 shares of the medical instruments supplier’s stock worth $1,060,000 after buying an additional 51 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $240.35 on Friday. The business has a 50 day simple moving average of $238.68 and a 200-day simple moving average of $240.71. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The company has a market capitalization of $69.44 billion, a price-to-earnings ratio of 56.95, a price-to-earnings-growth ratio of 1.94 and a beta of 0.45. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the prior year, the company earned $2.86 earnings per share. The firm’s revenue was up 4.6% compared to the same quarter last year. As a group, equities research analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date of this dividend is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 90.05%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Barclays raised their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.